 open noncomparative study doxazosin essential hypertension experience general practice Netherlands antihypertensive efficacy safety lipid effects doxazosin selective alpha general practice setting twenty-six patients study phases baseline period period patients mg doxazosin daily maintenance period weeks efficacy-evaluable patients therapy successes diastolic blood pressure equal mm Hg equal mm Hg reduction baseline equal mm Hg reduction baseline mean daily dose patients therapy success final visit systolic/diastolic blood pressures patients mm Hg mean baseline mm Hg investigators global assessment efficacy once-daily doxazosin therapy excellent good patients patients total side effects side effects mild moderate severity patients treatment adverse experiences investigators global assessment toleration excellent good patients Doxazosin significant decrease total cholesterol levels baseline final visit significant reduction risk score coronary heart disease basis Framingham Heart Study risk equation